TY - JOUR
T1 - Therapeutic Targeting of mTORC2 in mTORopathies
AU - Dentel, Brianne
AU - Escamilla, Christine Ochoa
AU - Tsai, Peter T.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/12/18
Y1 - 2019/12/18
N2 - Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies. Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies.
AB - Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies. Dysregulated mTOR contributes to neurodevelopmental dysfunction. A new study (Chen et al., 2019) demonstrates that suppression of mTORC2, not mTORC1, ameliorates survival, seizures, and abnormal behaviors in a Pten mutant model, highlighting mTORC2 as a potential therapeutic target in mTORopathies.
UR - http://www.scopus.com/inward/record.url?scp=85076914364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076914364&partnerID=8YFLogxK
U2 - 10.1016/j.neuron.2019.11.026
DO - 10.1016/j.neuron.2019.11.026
M3 - Comment/debate
C2 - 31951535
AN - SCOPUS:85076914364
SN - 0896-6273
VL - 104
SP - 1032
EP - 1033
JO - Neuron
JF - Neuron
IS - 6
ER -